Recombinant
RabMAb

Anti-MEK1 antibody [E342] (HRP) (ab193987)

Overview

  • Product name
    Anti-MEK1 antibody [E342] (HRP)
    See all MEK1 primary antibodies
  • Description
    Rabbit monoclonal [E342] to MEK1 (HRP)
  • Host species
    Rabbit
  • Conjugation
    HRP
  • Tested applications
    Suitable for: WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Cow
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human MEK1 aa 1-100 (N terminal). The exact sequence is proprietary.
    Database link: Q02750

  • Positive control
    • WB: A431 cells and cell lysate. IHC-P: FFPE human colon tissue sections.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab193987 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000. Detects a band of approximately 45 kDa (predicted molecular weight: 43 kDa).
IHC-P 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • Function
    Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
  • Tissue specificity
    Widely expressed, with extremely low levels in brain.
  • Involvement in disease
    Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similarities
    Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
    Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt
  • Database links
  • Alternative names
    • Dual specificity mitogen activated protein kinase kinase 1 antibody
    • Dual specificity mitogen-activated protein kinase kinase 1 antibody
    • ERK activator kinase 1 antibody
    • MAP kinase kinase 1 antibody
    • MAP kinase/Erk kinase 1 antibody
    • MAP2K1 antibody
    • MAPK/ERK kinase 1 antibody
    • MAPKK 1 antibody
    • MAPKK1 antibody
    • MEK 1 antibody
    • Mek1 antibody
    • MEKK1 antibody
    • Mitogen activated protein kinase kinase 1 antibody
    • MKK 1 antibody
    • MKK1 antibody
    • MP2K1_HUMAN antibody
    • PRKMK1 antibody
    • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1) antibody
    • Protein kinase mitogen activated, kinase 1 antibody
    see all

Images

  • IHC image of MEK1 staining in a section of formalin-fixed paraffin-embedded human normal colon*. The section was pre-treated using pressure cooker heat mediated antigen retrieval with sodium citrate buffer (pH6) for 30mins, and incubated overnight at +4°C with ab193987 at a working dilution of 1/500. DAB was used as the chromogen (ab103723), diluted 1/100 and incubated for 10min at room temperature. The section was counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    *Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

  • Anti-MEK1 antibody [E342] (HRP) (ab193987) at 1/5000 dilution + A431 (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 43 kDa
    Observed band size: 45 kDa (why is the actual band size different from the predicted?)


    Exposure time: 10 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab193987 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab193987 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab193987.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up